Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,196 matching trials from the live ClinicalTrials.gov search.
Filters: "blood pressure" Condition: Hypertension Clear all
Completed Phase 1 Interventional

A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure

NCT00537043
View directory record Official record
Conditions
Hypertension
Interventions
SK&F-105517 (COREG CR FDC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Hackensack, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 14, 2026, 5:17 PM EDT
Active, not recruiting Not applicable Interventional

Linkage, Empowerment, and Access to Prevent Hypertension

NCT05061108
View directory record Official record
Conditions
Hypertension, Blood Pressure, Cardiovascular Disease Other
Interventions
PAL2
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure

NCT03714776
View directory record Official record
Conditions
Mild Hypertension
Interventions
Placebo, ISIS 757456
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
6
States / cities
Tustin, California • Port Orange, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 14, 2026, 5:17 PM EDT
Terminated Phase 4 Interventional Results available

Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension

NCT03044314
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Iloprost and nitric oxide administration
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

NCT02603809
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg, Aprocitentan 50 mg, Lisinopril 20 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
74
States / cities
Fort Payne, Alabama • Chandler, Arizona • Peoria, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 4 Interventional

Vascular Improvement With Olmesartan Medoxomil Study

NCT00772499
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure, atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2008 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep and Circadian Mechanisms of Non-dipping Blood Pressure

NCT03558893
View directory record Official record
Conditions
Hypertension, Cardiovascular Risk Factor
Interventions
Forced Desynchrony
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 14, 2026, 5:17 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Preeclampsia: A Marker for Future Cardiovascular Risk in Women

NCT01519297
View directory record Official record
Conditions
Preeclampsia, Pregnancy Induced Hypertension
Interventions
Irbesartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 14, 2026, 5:17 PM EDT
Recruiting Not applicable Interventional

HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring

NCT07204756
View directory record Official record
Conditions
Postpartum, Hypertension, Hypertensive Disorder of Pregnancy
Interventions
2-Week Home Monitoring, 6-Week Home Monitoring
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 14, 2026, 5:17 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH

NCT03556020
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pemziviptadil (PB1046)
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
26
States / cities
Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 14, 2026, 5:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Military Health and Nutrition Examination Study

NCT06380322
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes, Dyslipidemias, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Fort Carson, Colorado • Hinesville, Georgia • Fort Campbell, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

NCT03635125
View directory record Official record
Conditions
JNC 7 Stage 1 or 2 Hypertension
Interventions
Nebivolol I, Nebivolol II, Baseline Washout Phase
Drug · Other
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Blood Pressure Checks for Diagnosing Hypertension (BP-CHECK)

NCT03130257
View directory record Official record
Conditions
Blood Pressure
Interventions
Clinic Blood Pressure Measurement, Home Blood Pressure Measurement, Kiosk Blood Pressure Measurement, 24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)
Diagnostic Test
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 85 Years
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 14, 2026, 5:17 PM EDT
Not yet recruiting Not applicable Interventional

Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities

NCT06915428
View directory record Official record
Conditions
Preterm Birth Complication, Preterm Birth, Preterm Birth Recurrence, Preeclampsia, Preeclampsia (PE), Hypertensive Disorders of Pregnancy, Support Program, Stress, Resilience, Psychological, Empowerment, Patient, Emotional Stress, Pregnancy, Pregnancy Complications, Pregnancy Induced Hypertension, Neonates and Preterm Infants, Cervical Insufficiency, Social Determinants of Health (SDOH), Cervical Shortening, Disparities in Pregnancy Complications, Disparities, Prenatal Care, Care Coordination
Interventions
Care coordination, Electronic massage, support gift #1, Support gift #2, Support gift #3, Support gift #4, Additional PTBCARE+ support, Stress reduction toolkit - Visit 1 (V1), PTBCARE+ mobile application (app) and website, Sleep, meditation, and Wellness app, Emergency low blood sugar kit, Low dose aspirin (LDA), Visit #2 Stress Reduction Toolkit
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
1,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 2Phase 3 Interventional

AVE7688 in Patients With Mild to Moderate Blood Pressure

NCT00284128
View directory record Official record
Conditions
Hypertension
Interventions
AVE7688, Losartan-potassium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Technology-based Intervention and Positive Psychological Training for Blood Pressure Control in African Americans

NCT03722667
View directory record Official record
Conditions
Hypertension, Self-management, Technology
Interventions
Technology-based Component, TechSupport
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
25 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)

NCT02392351
View directory record Official record
Conditions
Hypertension
Interventions
Renal Denervation (Vessix), Renal Angiography
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Miami Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

NCT02133872
View directory record Official record
Conditions
Hypertension
Interventions
Minocycline 50mg/d, Minocycline 100mg/d, Minocycline 200mg/d
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 4 Interventional Results available

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

NCT02299388
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
Interventions
Liraglutide or Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Mi Propio Camino Intervention RCT for Blood Pressure Medication Adherence

NCT04585594
View directory record Official record
Conditions
Hypertension, Medication Adherence
Interventions
Mi Propio Camino (MPC), Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 14, 2026, 5:17 PM EDT
Active, not recruiting Not applicable Interventional Results available

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

NCT03614260
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Paradise Renal Denervation System, Renal Angiogram
Device · Procedure
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

NCT05459688
View directory record Official record
Conditions
Hypertension
Interventions
CIN-107
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
36
States / cities
Saraland, Alabama • Huntington Park, California • Lincoln, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 14, 2026, 5:17 PM EDT
Recruiting Phase 3 Interventional

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Interventions
Vicadrostat, Empagliflozin, Placebo matching Vicadrostat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
11,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
208
States / cities
Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 14, 2026, 5:17 PM EDT